Testing colistimethate for CRE infection in hospitalized patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 85 years old and currently in the hospital.
- You have a hospital-acquired pneumonia (lung infection from being in the hospital) or a bloodstream infection caused by a hard-to-treat bacteria called CRE.
- You have a positive test (like a culture or rapid test) showing CRE in your lungs or blood within the last 5 days.
- Your illness severity score (APACHE II) is between 10 and 30.
- You have not received more than 2 days of a similar antibiotic (polymyxin) in the last 72 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial tests whether giving healthy bacteria through capsules (a fecal transplant) can help get rid of CRE, a type of bacteria that is hard to treat because it resists many antibiotics. If successful, this could reduce the risk of serious infections.
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Carbapenem-Resistant Enterobacteriaceae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.